Last reviewed · How we verify

NCT05640453

Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting

Recruiting now Phase 4 Last updated 25 June 2025
What this trial tests

Phase 4 trial testing Pregabalin in Pregabalin in 70 participants. Currently enrolling.

Timeline
15 December 2022
Primary endpoint
15 May 2026
15 May 2026

Quick facts

Lead sponsorTanta University
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment70
Start date15 December 2022
Primary completion15 May 2026
Estimated completion15 May 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

65 and older, any sex, with Pregabalin or Delirium Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pregabalin

Trials testing the same drug.

Other recruiting trials for Pregabalin

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05640453.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing